Stay updated on SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.

Latest updates to the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page
- ChecktodayChange DetectedThe site footer now identifies the ClinicalTrials.gov version as v3.8.1 instead of v3.8.0. The study record content remains unchanged.SummaryDifference0.0%

- Check7 days agoChange DetectedThe clinical trial’s full study record is displayed, covering its design, eligibility criteria, treatment arms, outcomes, and participating locations, along with results and study documents. It replaces the previous forbidden-error page.SummaryDifference78%

- Check14 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedAn NIH banner announces a terminology change from “Artificial Intelligence” to “Super Intelligence” across NIH content. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error with a minimal header and a Home link, replacing the previous study record content and attached documents; users cannot view the study details.SummaryDifference20%

Stay in the know with updates to SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.